Polymyositis and dermatomyositis - NYSORA

Explore NYSORA knowledge base for free:

Table of Contents

Contributors

Polymyositis and dermatomyositis

Polymyositis and dermatomyositis

Learning objectives

  • Definition of polymyositis and dermatomyositis
  • Management of polymyositis and dermatomyositis

Definition and mechanisms

  • Myositis is the name for a group of rare conditions such as polymyositis and dermatomyositis, leading to weak, painful, or aching muscles
  • Polymyositis and dermatomyositis are autoimmune myopathies characterized by inflammation and weakness of proximal skeletal muscles 
  • Characteristically there is a rise in serum enzymes derived from muscle, e.g. creatine phosphokinase (CPK) and myoglobin may be released leading to myoglobinuria
  • Dermatomyositis, unlike polymyositis, is associated with a variety of characteristic skin manifestations
  • The cause is unknown, maybe an immune reaction triggered by a virus or tumor
  • Both occur almost two times more often in women than in men
  • It can occur at any age

Signs and symptoms

  • Both polymyositis and dermatomyositis have symptoms in common with sclerosis or sometimes systemic lupus erythematosus:
    • Muscle weakness
    • Contraction of the arms and legs
    • Shortness of breath
    • Difficulty swallowing
    • Muscle tenderness or pain
    • Raynaud’s phenomenon
    • Fever
    • Feeling tired
    • Weight loss
  • If dermatomyositis occurs along with polymyositis, symptoms may also include:
    • Skin rash
    • Swelling around the eye
    • Swelling at the base and sides of the fingernails
    • Splitting of the skin of the fingers

Diagnosis

  • Laboratory findings:
    • Elevations in serum creatine kinase, lactate dehydrogenase, aldolase, and aminotransferases
    • Myositis-specific autoantibodies
  • Muscle biopsy
  • Electromyogram
  • MRI

Treatment

  • Corticosteroids
  • Immunosuppressive drugs: methotrexate, cyclophosphamide, chlorambucil, azathioprine, cyclosporine
  • Immunoglobulin therapy
  • Exercise is important to reduce swelling and to build or restore muscle strength

Management

Polymyositis and dermatomyositis

Perioperative management of polymyositis and dermatomyositis, malignant hyperthermia, suxamethonium, hyperkalemia, nondepolarizing neuromuscular blocking agents, rapid sequence induction

Suggested reading

  • Christopher-Stine L, Vleugels An Amato AA. 2022 Clinical manifestations of dermatomyositis and polymyositis in adults. Up To Date. 
  • Pollard BJ, Kitchen, G. Handbook of Clinical Anaesthesia. Fourth Edition. CRC Press. 2018. 978-1-4987-6289-2.
  • Raychaudhuri SP, Mitra A. Polymyositis and dermatomyositis: Disease spectrum and classification. Indian J Dermatol. 2012;57(5):366-370.
  • Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet. 2003;362(9388):971-982.

We would love to hear from you. If you should detect any errors, email us customerservice@nysora.com

Upcoming Events View All